RxDoctor Payments Data

Misty Cain

Nurse Practitioner · Farmington, MONPI 1013548403

Payments from drug & device makers

$577in general payments, 2019–2025

Across 24 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$154
  • Abiomed$39
  • Lilly USA, LLC$39
  • Boehringer Ingelheim$39
  • UCB, Inc.$37
  • AstraZeneca$32
  • plus $238 from 12 others

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$577 in reported general payments places this provider in the 70th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$59,908
Medicare patients
394
Services billed
996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$94,584
OzempicSemaglutide50$49,036
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf40$44,895
TrulicityDulaglutide27$27,247
JanuviaSitagliptin Phosphate112$24,463
JardianceEmpagliflozin92$17,937
EliquisApixaban92$17,934
MounjaroTirzepatide16$15,928
MyrbetriqMirabegron82$15,689
Breo ElliptaFluticasone/Vilanterol37$15,582
FarxigaDapagliflozin Propanediol72$10,465
Levocetirizine Dihydrochloride1,349$10,207
Esomeprazole Magnesium224$10,156
Spiriva HandihalerTiotropium Bromide18$9,809
Spiriva RespimatTiotropium Bromide17$9,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$49,03650 claims
Lilly USA, LLCTrulicity, Mounjaro$39$43,17443 claims
Boehringer IngelheimJardiance, Spiriva Respimat$39$27,447109 claims
AstraZenecaFarxiga, Symbicort$32$14,04488 claims
Johnson & JohnsonXarelto$25$8,12752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Farmington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →